ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2013

Cardiovascular Disease

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,914Medicare Part D Prescriptions Filled, Including Refills

Rank: 2 out of 55

$609K Total Retail Price of All Prescriptions

Rank: 2 out of 55

330 Patients Receiving at Least One Drug in Part D
75% Patients 65 Years and Older
71% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg 81928cdb0ebe162ff75cf405bfacadd396bf3ec84bc467b6f3e612dd63daa776 Average for
this specialty
in District of Columbia
Lower avg 72b1978e1dcc0b845f89d17d692cfff7aeaf8d8bce70310d8bfc535db2daf62a

Schedule Two
Controlled Substances

13% of this provider’s 330 patients filled at least one prescription for a schedule two drug, compared to an average of 1%.

Schedule Three
Controlled Substances

9% of this provider’s 330 patients filled at least one prescription for a schedule three drug, compared to an average of 2%.

Brand Name Drugs

32% of this provider’s prescriptions were for brand-name drugs, compared to an average of 27%.

Prescription Price

$61 was the average price of a prescription from this provider, compared to $71 among peers.

Prescriptions per Patient

30 is the average number of prescriptions (including refills) per patient, compared to an average of 13.


This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

B

A benzodiazepine, or tranquilizer. More » The American Geriatrics Society says these drugs increase the risk of cognitive impairment, delirium, falls and fractures in older adults.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled with Refills Prescriptions
to 65+
Patients Recieving this Drug Category For this Prescriber For All Prescribers in
This Specialty in District of Columbia
FUROSEMIDE 505 378 94 1 5
AMLODIPINE BESYLATE 465 325 78 2 1
METOPROLOL SUCCINATE 360 263 52 3 4
CLOPIDOGREL 295 257 45 4 8
METFORMIN HCL 283 197 49 5 15
LISINOPRIL 245 139 41 6 2
SIMVASTATIN 232 184 43 7 7
ATORVASTATIN CALCIUM 228 161 41 8 3
OXYCODONE-ACETAMINOPHEN 188 100 39 S2 9 32
DIOVAN 162 132 20 10 16
IBUPROFEN 157 107 33 11 29
LEVOTHYROXINE SODIUM 137 116 19 12 25
HYDROCHLOROTHIAZIDE 128 76 24 13 9
CRESTOR 116 111* 21 14 12
POTASSIUM CHLORIDE 112 92 23 15 39
ALPRAZOLAM 110 60 22 B 16 49
KLOR-CON M10 108 94 26 17 50
METOPROLOL TARTRATE 107 102* 20 18 13
CARVEDILOL 105 76 22 19 6
EXFORGE 101 82 15 20 68
ACETAMINOPHEN-CODEINE 100 81 24 S3 21 18
KLOR-CON 10 97 92* 29 22 70
CYCLOBENZAPRINE HCL 97 33 22 R 22 70
NAMENDA 97 97 18 22 70
VALSARTAN-HYDROCHLOROTHIAZIDE 97 92* 16 22 28
PANTOPRAZOLE SODIUM 94 89* 20 26 39
GLIPIZIDE 90 51 13 27 38
AZITHROMYCIN 83 49 46 28 74
TAMSULOSIN HCL 81 56 14 29 47
ATENOLOL 79 51 11 30 20
HYDRALAZINE HCL 76 71* 16 31 14
FLUTICASONE PROPIONATE 75 70* 21 32 60
LOSARTAN POTASSIUM 75 75 11 32 11
NAPROXEN 67 56 14 34 51
ADVAIR DISKUS 67 38 15 34 55
GLIMEPIRIDE 67 <11 <11 34 48
ALLOPURINOL 66 49 17 37 62
ZOLPIDEM TARTRATE 65 43 16 38 42
VOLTAREN 64 59* 27 39 58
PROAIR HFA 63 47 18 40 35
DEXILANT 62 <11 <11 41 81
CIPROFLOXACIN HCL 61 56* 27 42 82
SPIRONOLACTONE 59 <11 <11 43 19
GABAPENTIN 59 36 16 43 34
NEXIUM 57 52* 14 45 30
OMEPRAZOLE 57 32 11 45 23
JANUVIA 55 35 11 47 86
WARFARIN SODIUM 54 37 17 48 10
NIFEDIPINE ER 52 47* 11 49 22
SPIRIVA 52 <11 <11 49 52
COLCRYS 51 21 11 51 45
About This Data

Prescribing data from Medicare’s prescription drug benefit, known as Part D, was compiled and released by the Centers for Medicare and Medicaid Services, the federal agency that oversees the program. ProPublica combined that data with additional information released by CMS. The data for 2013 includes nearly 1.4 billion prescriptions written by 1.3 million doctors, nurses and other providers. This database lists about 410,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths of these prescriptions went to patients 65 and older; the rest were for disabled patients Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to checkup@propublica.org and we will update your information. If you have other questions about this data, send a note to checkup@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Dec. 13, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.